Recent research shows that Tfh cells are not the only players in T cell/B cell interactions leading to autoimmune disease. There are also populations of extrafollicular T helper cells that can affect T cell/B cell interactions.
M. Elaine Husni, MD, MPH, Vice Chair of the Department of Rheumatic & Immunologic Diseases at the Cleveland Clinic, Ohio, said given the number of new therapeutics available for PsA, it’s important for rheumatologists to become familiar with the new options in terms of mechanisms of action, efficacy in various domains of disease presentations, and…
Gordon Starkebaum, MD, said the session’s goal was to cover useful information and also to engender discussion. The audience will be able to submit questions for the expert panel during the session.
At different stages in research, type 1 interferon (IFN) has been identified as a causal factor in lupus, a biomarker, and a potential therapeutic target. IFN can play all three roles, but recently there has been much debate about whether IFN is a therapeutic target.
Students of all ages and levels rely on high-quality feedback to improve their knowledge and skills — making the delivery of effective, real-time feedback.
To bring rheumatologists up to date on various recent proposals to restrict reproductive healthcare for women and how that may impact care of their patients, a rheumatologist will join an attorney to review pending laws and their status during a session on Tuesday.
“A better way to think about immunodeficiency is as immune dysregulation. It is paradoxical, but many patients with immunodeficiencies are also at increased risk for autoimmunity and for granuloma formation,”” said Mahta Mortezavi, MD.
New technologies make it possible to measure tens of thousands of cells at once, giving researchers an opportunity for improving our understanding of disease on a molecular level.
A Monday afternoon Clinical Practice session will examine several comorbidities that can complicate management and affect longterm prognoses for patients.
“There is a great need to recognize when to treat this disease, because, as with many of our other rheumatic diseases, there’s a window of opportunity,” said Suzanne Li, MD, PhD.